Diego Falla-Sepulveda

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Astrocyte-driven small vessel disease is an early, amyloid-independent feature of PSEN1 E280A familial Alzheimer's disease.

Astrocyte-driven small vessel disease is an early, amyloid-independent feature of PSEN1 E280A familial Alzheimer's disease.

Journal: bioRxiv : the preprint server for biology
Published: August 01, 2026

Presymptomatic pharmacological inhibition of mGluR5 improves survival in a mouse model of prion diseases.

Presymptomatic pharmacological inhibition of mGluR5 improves survival in a mouse model of prion diseases.

Journal: Acta neuropathologica communications
Published: September 10, 2025

ApoE4 Homozygosity Is Associated With Increased Microglia Activation in Fatal COVID-19.

ApoE4 Homozygosity Is Associated With Increased Microglia Activation in Fatal COVID-19.

Journal: Neuropathology : official journal of the Japanese Society of Neuropathology
Published: August 18, 2025

Comorbidities in early-onset sporadic versus presenilin-1 mutation-associated Alzheimer disease dementia: Evidence for dependency on Alzheimer disease neuropathological changes.

Comorbidities in early-onset sporadic versus presenilin-1 mutation-associated Alzheimer disease dementia: Evidence for dependency on Alzheimer disease neuropathological changes.

Journal: Journal of neuropathology and experimental neurology
Published: December 10, 2024

Driving research on successful aging and neuroprotection in Latin America: Insights from the inaugural symposium on brain resilience and healthy longevity.

Driving research on successful aging and neuroprotection in Latin America: Insights from the inaugural symposium on brain resilience and healthy longevity.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: November 26, 2024

Protective genetic variants against Alzheimer's disease.

Protective genetic variants against Alzheimer's disease.

Journal: The Lancet. Neurology
Published: September 30, 2024

APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease.

APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease.

Journal: The New England journal of medicine
Published: June 20, 2024

Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases.

Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases.

Journal: Acta neuropathologica
Published: April 24, 2024

APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer's cases.

APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer's cases.

Journal: Frontiers in molecular neuroscience
Published: January 20, 2024

The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact.

The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: October 31, 2023

Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer's disease profile and possible mechanisms of disease protection.

Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer's disease profile and possible mechanisms of disease protection.

Journal: Neuron
Published: May 16, 2023

Genetic modifiers of cognitive decline in PSEN1 E280A Alzheimer's disease.

Genetic modifiers of cognitive decline in PSEN1 E280A Alzheimer's disease.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 28, 2023
Showing 1-12 of 54

Last Updated: 09/26/2026